Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

VICC toll-free number 1-877-936-8422

Childhood Cancers

The Division of Hematology and Oncology at Monroe Carell Jr. Children's Hospital at Vanderbilt includes a dedicated faculty and staff who work together as a team in the diagnosis and treatment of children with cancer or blood diseases. The division also supports a variety of clinical and research programs, a consultation service, and a fellowship training program.

Clinical Trials for Pediatric Cancers

24 Open Trials

Trial Type Protocol No. &
Open Date
Summary

Basic Science

VICCPED1544

12/14/2015

Michigan Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository

Basic Science

COGAALL08B1

10/18/2010

Classification of Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)

Basic Science

COGAALL05B1

12/01/2006

A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens

Basic Science

COGANHL04B1

09/14/2006

Rare and Cutaneous Non-Hodgkin Lymphoma Registry

Health Services Research

VICCNCPED1513

08/28/2015

An Observational, Multi-Center Study to Evaluate the Safety of Deferasirox in the Treatment of Pediatric Patients with Non-Transfusion-Dependent Iron Overload

Health Services Research

VICCPED14127

01/08/2015

Infectious Disease Outcomes in Pediatric Oncology Patients

Health Services Research

VICCREACH1447

04/16/2014

Retinoblastoma Survivor Study (RBSS)

Other

COGAPEC14B1

01/20/2016

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Other

VICCPED0710

03/16/2007

Long Term Effects for Childhood Cancer Survivors

Other

COGALTE03N1

04/20/2005

Key Adverse Events after Childhood Cancer

Supportive Care

VICCPED1570

04/28/2016

A phase III, randomized, placebo-controlled clinical trial to study the efficacy and safety of MK-0517/fosaprepitant and ondansetron versus ondansetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric subjects receiving emetogenic chemotherapy

Supportive Care

VICCSAR1568

05/23/2013

Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center Randomized Controlled Study Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections with Endoprosthetic Replacements

Supportive Care

COGACCL0933

11/16/2011

A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)

Treatment

VICCPHI1502

06/20/2016

A phase I/II open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with NUT midline carcinoma (NMC) and other cancers

Treatment

COGAAML1331

04/28/2016

A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide and All-Trans Retinoic Acid

Treatment

VICCPED1537

04/28/2016

T2014-001 A Phase I Trial of Temsirolimus (CC-779, Pfizer, Inc.) in Combination with Etoposide and Cyclophosphamide in Children with Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma

Treatment

COGAOST1321

04/07/2016

Phase 2 Study of Denosumab (IND# 127430, NSC# 744010), a RANK Ligand Antibody, for Recurrent or Refractory Osteosarcoma

Treatment

COGAALL1331

02/01/2016

Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND# 117467, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Treatment

VICCPED1489

01/07/2016

Molecular-Guided Therapy for the Treatment of Patients with Relapsed and Refractory Childhood Cancers

Treatment

COGAEWS1221

12/02/2015

Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008, IND# 120449) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma

Treatment

COGAALL1231

05/13/2015

A Phase III Randomized Trial Investigating Bortezomib NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

Treatment

COGANBL1232

08/20/2014

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

Treatment

VICCPED1249

08/06/2012

An Open Label, Expanded Access Protocol using 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy in Patients with Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Treatment

COGAALL1131

04/05/2012

A Phase III Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND #73789, NSC# 606869) in the Very High Risk Stratum